PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Behçet’s disease (BD) is an inflammatory autoimmune disease characterized by relapsing genital ulcers, ocular involvement, and intestinal disorders. Evaluate serum levels of circular RNA (circRNA) ...
(RTTNews) - Shares of Soligenix Inc. (SNGX) are up more than 20% at $1.50 in premarket hours, following encouraging results from its Phase 2a proof of concept study of SGX945 in the treatment of ...
The EULAR recommendations for the management of Behçet’s syndrome were first published in 2008, and updated in 2018. Since that time, new evidence has become available, including trials of biologic ...
Hosted on MSN
SNGX stock slumps to record low after lymphoma trial fails – all eyes now on Behçet’s disease treatment
・The trial was evaluating HyBryte in a rare form of cancer with limited treatment options. ・The company also plans to assess whether certain patient groups could still benefit from the therapy. ・Last ...
Hatemi, one of the two co-convenors of the EULAR task force behind the revised recommendations, said there had been changes not just to the content but also to the wording of the recommendations to ...
Soligenix Inc.’s phase IIa study of SGX-945 (dusquetide) for treating oral ulcers in those with Behçet's disease showed biological efficacy in the proof-of-concept study. The positive results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results